Format
Sort by

Send to

Choose Destination

Search results

Items: 17

1.

Brief Report: Association of Myositis Autoantibodies, Clinical Features, and Environmental Exposures at Illness Onset With Disease Course in Juvenile Myositis.

Habers GE, Huber AM, Mamyrova G, Targoff IN, O'Hanlon TP, Adams S, Pandey JP, Boonacker C, van Brussel M, Miller FW, van Royen-Kerkhof A, Rider LG; Childhood Myositis Heterogeneity Study Group.

Arthritis Rheumatol. 2016 Mar;68(3):761-8. doi: 10.1002/art.39466.

PMID:
26474155
2.

Early illness features associated with mortality in the juvenile idiopathic inflammatory myopathies.

Huber AM, Mamyrova G, Lachenbruch PA, Lee JA, Katz JD, Targoff IN, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Care Res (Hoboken). 2014 May;66(5):732-40. doi: 10.1002/acr.22212.

3.

[Metabolic myopathies].

Papazian Ó, Rivas-Chacón R.

Rev Neurol. 2013 Sep 6;57 Suppl 1:S65-73. Review. Spanish.

4.

The myositis autoantibody phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Shah M, Mamyrova G, Huber AM, Rice MM, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jul;92(4):223-43. doi: 10.1097/MD.0b013e31829d08f9.

5.

Brief report: ultraviolet radiation exposure is associated with clinical and autoantibody phenotypes in juvenile myositis.

Shah M, Targoff IN, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Rheum. 2013 Jul;65(7):1934-41. doi: 10.1002/art.37985.

6.

The clinical phenotypes of the juvenile idiopathic inflammatory myopathies.

Shah M, Mamyrova G, Targoff IN, Huber AM, Malley JD, Rice MM, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Medicine (Baltimore). 2013 Jan;92(1):25-41. doi: 10.1097/MD.0b013e31827f264d.

7.

Rituximab in the treatment of refractory adult and juvenile dermatomyositis and adult polymyositis: a randomized, placebo-phase trial.

Oddis CV, Reed AM, Aggarwal R, Rider LG, Ascherman DP, Levesque MC, Barohn RJ, Feldman BM, Harris-Love MO, Koontz DC, Fertig N, Kelley SS, Pryber SL, Miller FW, Rockette HE; RIM Study Group.

Arthritis Rheum. 2013 Feb;65(2):314-24. doi: 10.1002/art.37754.

8.

Deficiency of interleukin-1 receptor antagonist responsive to anakinra.

Schnellbacher C, Ciocca G, Menendez R, Aksentijevich I, Goldbach-Mansky R, Duarte AM, Rivas-Chacon R.

Pediatr Dermatol. 2013 Nov-Dec;30(6):758-60. doi: 10.1111/j.1525-1470.2012.01725.x. Epub 2012 Apr 4.

9.

Evidence of acute Mycoplasma infection in a patient with incomplete and atypical kawasaki disease: a case report.

Ebrahim M, Gabay M, Rivas-Chacon RF.

Case Rep Med. 2011;2011:606920. doi: 10.1155/2011/606920. Epub 2011 Dec 10.

10.

Environmental factors preceding illness onset differ in phenotypes of the juvenile idiopathic inflammatory myopathies.

Rider LG, Wu L, Mamyrova G, Targoff IN, Miller FW; Childhood Myositis Heterogeneity Collaborative Study Group.

Rheumatology (Oxford). 2010 Dec;49(12):2381-90. doi: 10.1093/rheumatology/keq277. Epub 2010 Aug 27.

11.

Cytokine gene polymorphisms as risk and severity factors for juvenile dermatomyositis.

Mamyrova G, O'Hanlon TP, Sillers L, Malley K, James-Newton L, Parks CG, Cooper GS, Pandey JP, Miller FW, Rider LG; Childhood Myositis Heterogeneity Collaborative Study Group.

Arthritis Rheum. 2008 Dec;58(12):3941-50. doi: 10.1002/art.24039.

12.

Predictors of acquired lipodystrophy in juvenile-onset dermatomyositis and a gradient of severity.

Bingham A, Mamyrova G, Rother KI, Oral E, Cochran E, Premkumar A, Kleiner D, James-Newton L, Targoff IN, Pandey JP, Carrick DM, Sebring N, O'Hanlon TP, Ruiz-Hidalgo M, Turner M, Gordon LB, Laborda J, Bauer SR, Blackshear PJ, Imundo L, Miller FW, Rider LG; Childhood Myositis Heterogeneity Study Group.

Medicine (Baltimore). 2008 Mar;87(2):70-86. doi: 10.1097/MD.0b013e31816bc604.

13.

Systemic lupus erythematosus in a patient treated with etanercept for polyarticular juvenile rheumatoid arthritis.

Bout-Tabaku S, Rivas-Chacon R, Restrepo R.

J Rheumatol. 2007 Dec;34(12):2503-4. No abstract available.

14.

Duration of illness is an important variable for untreated children with juvenile dermatomyositis.

Pachman LM, Abbott K, Sinacore JM, Amoruso L, Dyer A, Lipton R, Ilowite N, Hom C, Cawkwell G, White A, Rivas-Chacon R, Kimura Y, Ray L, Ramsey-Goldman R.

J Pediatr. 2006 Feb;148(2):247-53.

PMID:
16492437
15.

History of infection before the onset of juvenile dermatomyositis: results from the National Institute of Arthritis and Musculoskeletal and Skin Diseases Research Registry.

Pachman LM, Lipton R, Ramsey-Goldman R, Shamiyeh E, Abbott K, Mendez EP, Dyer A, Curdy DM, Vogler L, Reed A, Cawkwell G, Zemel L, Sandborg C, Rivas-Chacon R, Hom C, Ilowite N, Gedalia A, Gitlin J, Borzy M.

Arthritis Rheum. 2005 Apr 15;53(2):166-72.

16.

Juvenile rheumatoid arthritis: benefits from massage therapy.

Field T, Hernandez-Reif M, Seligman S, Krasnegor J, Sunshine W, Rivas-Chacon R, Schanberg S, Kuhn C.

J Pediatr Psychol. 1997 Oct;22(5):607-17.

17.

Morbidity associated with long-term methotrexate therapy in juvenile rheumatoid arthritis.

Graham LD, Myones BL, Rivas-Chacon RF, Pachman LM.

J Pediatr. 1992 Mar;120(3):468-73.

PMID:
1538301
Items per page

Supplemental Content

Loading ...
Write to the Help Desk